Literature DB >> 16674361

Health and economic outcomes modeling practices: a suggested framework.

M T Halpern1, B R Luce, R E Brown, B Geneste.   

Abstract

In the field of outcomes research, modeling is increasingly being used to assess costs and outcomes associated with healthcare interventions. However, there is little standardization with regard to modeling practices, and the quality and usefulness of economic and health outcomes models may vary. We propose the following set of recommendations for good modeling practices to be used in both the development and review of models. These recommendations are divided into three sections: criteria to be addressed before model development or initial review; criteria used during model development or evaluation; and criteria used following model development. These recommendations also include examples regarding different modeling techniques and practices as well as a checklist (see appendix) to assess model correspondence with the recommendations. We hope that the use of good practice recommendations for modeling will not only improve the development and review of models but also lead to greater acceptance of this methodology.

Year:  1998        PMID: 16674361     DOI: 10.1046/j.1524-4733.1998.120131.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  23 in total

1.  Development of the health and economic consequences of smoking interactive model.

Authors:  M E Orme; S L Hogue; L M Kennedy; A C Paine; C Godfrey
Journal:  Tob Control       Date:  2001-03       Impact factor: 7.552

Review 2.  Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application.

Authors:  M Sculpher; E Fenwick; K Claxton
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

3.  Expert judgement in pharmacoeconomic studies. Guidance and future use.

Authors:  C Evans; B Crawford
Journal:  Pharmacoeconomics       Date:  2000-06       Impact factor: 4.981

Review 4.  Testing the validity of cost-effectiveness models.

Authors:  C McCabe; S Dixon
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

5.  A proposed model for economic evaluations of major depressive disorder.

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon; Jodi Gray
Journal:  Eur J Health Econ       Date:  2011-06-02

Review 6.  Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment.

Authors:  Zoë Philips; Laura Bojke; Mark Sculpher; Karl Claxton; Su Golder
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 7.  A review of health care models for coronary heart disease interventions.

Authors:  K Cooper; S C Brailsford; R Davies; J Raftery
Journal:  Health Care Manag Sci       Date:  2006-11

8.  Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: a stochastic economic evaluation.

Authors:  Jonathan Karnon; Jackie Brown
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 9.  A scoping review of simulation modeling in built environment and physical activity research: Current status, gaps, and future directions for improving translation.

Authors:  Leah Frerichs; Natalie R Smith; Kristen Hassmiller Lich; Todd K BenDor; Kelly R Evenson
Journal:  Health Place       Date:  2019-04-24       Impact factor: 4.078

Review 10.  The economics of selective serotonin reuptake inhibitors in depression: a critical review.

Authors:  L Frank; D A Revicki; S V Sorensen; Y C Shih
Journal:  CNS Drugs       Date:  2001-01       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.